To B or not to B? That is the question, for global mother-to-child HIV-1 transmission prevention programs.

about

To B or not to B? That is the question, for global mother-to-child HIV-1 transmission prevention programs.

Item

http://www.wikidata.org/entity/Q42284209

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

To B or not to B? That is the ...... nsmission prevention programs.

@en

To B or not to B? That is the ...... nsmission prevention programs.

@nl

type

Item

label

To B or not to B? That is the ...... nsmission prevention programs.

@en

To B or not to B? That is the ...... nsmission prevention programs.

@nl

prefLabel

To B or not to B? That is the ...... nsmission prevention programs.

@en

To B or not to B? That is the ...... nsmission prevention programs.

@nl

P1476

To B or not to B? That is the ...... nsmission prevention programs.

@en

P2093

Fredrick Sawe

http://www.w3.org/2001/XMLSchema#string

P2860

Prevention of HIV-1 infection with early antiretroviral therapy

Antiretroviral prophylaxis for HIV prevention in heterosexual men and women

The cost-effectiveness of preventing mother-to-child transmission of HIV in low- and middle-income countries: systematic review

Integrating prevention of mother-to-child HIV transmission programs to improve uptake: a systematic review.

Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel.

Realities and Challenges of a Five Year Follow Up of Mother and Child Pairs on a PMTCT Program in Zimbabwe.

Evaluating the cost-effectiveness of combination antiretroviral therapy for the prevention of mother-to-child transmission of HIV in Uganda.

Cost-effectiveness of World Health Organization 2010 guidelines for prevention of mother-to-child HIV transmission in Zimbabwe

Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda.

Time from human immunodeficiency virus seroconversion to reaching CD4+ cell count thresholds <200, <350, and <500 Cells/mm³: assessment of need following changes in treatment guidelines.

P304

447-449

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/CID/CIS862

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Shahin Lockman

P577

2012-11-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233829996

http://www.w3.org/2001/XMLSchema#string

P698

23204036

http://www.w3.org/2001/XMLSchema#string

P921

HIV transmission

prevention of HIV/AIDS